Incyte Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Bill Meury

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.4yrs
Yönetim Kurulu ortalama görev süresi	7.8yrs

Son yönetim güncellemeleri

Recent updates

Incyte Q1 Preview: The Growth Story Remains Intact

Apr 23

Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 31

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Aug 14

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Aug 06

CEO

Bill Meury (57 yo)

less than a year

Görev süresi

Mr. William J. Meury, also known as Bill, is Director of Uniquity Bio, Inc. Mr. Meury served as the Chief Executive Officer & Director of Anthos Therapeutics, Inc. since April 2024. He is CEO & Director of...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pablo Cagnoni	President and Global Head of Research & Development	less than a year	US$7.90m	0.0026% $ 496.7k
Steven Stein	Executive VP	11.1yrs	US$5.98m	0% $ 0
William Meury	CEO & Director	less than a year	Veri yok	Veri yok
Thomas Tray	Principal Financial Officer	4.1yrs	Veri yok	0.0039% $ 754.7k
Michael Morrissey	Executive VP & Head of Global Technical Operations	10.3yrs	Veri yok	0.0058% $ 1.1m
Alexis Smith	Vice President & Head of Investor Relations	no data	Veri yok	Veri yok
Richard Hoffman	Executive VP & General Counsel	less than a year	Veri yok	Veri yok
Pamela Murphy	Vice President of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok
Soni Basi	Executive VP & Chief Human Resources Officer	less than a year	Veri yok	Veri yok
James Lee	Group VP	no data	Veri yok	Veri yok
Denise Brashear	VP & Head of Global Communications	4.3yrs	Veri yok	Veri yok
Xiaozhao Wang	Associate VP & Head of Medicinal Chemistry	3.4yrs	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim: INCY 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
William Meury	CEO & Director	less than a year	Veri yok	Veri yok
Jean-Jacques Bienaime	Independent Director	11.3yrs	US$518.15k	0.0092% $ 1.8m
Julian Baker	Independent Chairman of the Board	24.4yrs	US$552.15k	0.14% $ 27.0m
Otis Brawley	Independent Director	4.6yrs	US$494.15k	0.0044% $ 845.2k
Jacqualyn Fouse	Independent Director	9.3yrs	US$505.65k	0.0084% $ 1.6m
Edmund Harrigan	Independent Director	6.3yrs	US$521.65k	0.0094% $ 1.8m
Katherine High	Independent Director	6.1yrs	US$494.15k	0.0054% $ 1.0m
Paul Clancy	Independent Director	11.3yrs	US$519.15k	0.011% $ 2.1m

7.8yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: INCY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/23 08:13
Gün Sonu Hisse Fiyatı	2026/04/23 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Incyte Corporation 43 Bu analistlerden 21, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jasper Hellweg	Argus Research Company
Thomas Russo	Baird
Peter Lawson	Barclays

Incyte Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Incyte Corporation Announces Executive Changes

Executive VP & Chief Medical Officer recently sold US$1.6m worth of stock

Insider recently sold US$5.7m worth of stock

Incyte Corporation Announces Resignation of Hervé Hoppenot from Board of Directors, Effective December 12, 2025

Executive Officer notifies of intention to sell stock

Executive VP & Chief Medical Officer recently sold US$2.3m worth of stock

Recent updates

Incyte Q1 Preview: The Growth Story Remains Intact

Incyte Highlights New Phase 3 Tafasitamab Data At the 2026 American Society of Clinical Oncology Annual Meeting

Incyte Corporation to Report Q1, 2026 Results on Apr 28, 2026

Incyte Announces New Positive 54-Week Data for Povorcitinib in Hidradenitis Suppurativa

Incyte Corporation Announces Executive Changes

Incyte Highlights Late-Breaking Hidradenitis Suppurativa Data And Features Ruxolitinib Cream And Povorcitinib At The American Academy Of Dermatology Annual Meeting

Incyte Announces European Commission Approval of Zynyz (Retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Provides Earnings Guidance for the Fiscal Year 2026

Incyte Announces Positive CHMP Opinion for Zynyz®? (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Incyte Corporation to Report Q4, 2025 Results on Feb 10, 2026

Executive VP & Chief Medical Officer recently sold US$1.6m worth of stock

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as First-Line Treatment for Diffuse Large B-Cell Lymphoma

New major risk - Revenue and earnings growth

Insider recently sold US$5.7m worth of stock

Incyte Announces European Commission Approval of Minjuvi (Tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Incyte Corporation Announces Resignation of Hervé Hoppenot from Board of Directors, Effective December 12, 2025

Executive Officer notifies of intention to sell stock

Incyte Announces New Positive Data for INCA033989, Its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented At ASH 2025

Executive VP & Chief Medical Officer recently sold US$2.3m worth of stock

Incyte Corporation Announces Executive Changes

Price target increased by 7.8% to US$94.90

Incyte Announces Positive CHMP Opinion for Minjuvi (Tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Advisor to CEO & Director recently sold US$20m worth of stock

Advisor to CEO & Director notifies of intention to sell stock

Price target increased by 7.9% to US$92.59

Investor sentiment improves as stock rises 17%

Consensus EPS estimates increase by 13%

Incyte Corporation Announces More Than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

Insufficient new directors

Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Earnings Guidance for the Fiscal Year 2025

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Eli Lilly and Company's Baricitinib Delivers Near- Complete Scalarched Hair Regrowth At One Year for Adoption of Baricitinib

Incyte Announces Phase 1 Results for Its Tgfbr2xpd-1 Bispecific Antibody in Advanced Colorectal Cancer and Kras G12d Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

Incyte Corporation to Report Q3, 2025 Results on Oct 28, 2025

Incyte Corporation Appoints Thomas Tray as Principal Financial Officer, Effective as of September 16, 2025

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer, Effective September 22, 2025

Incyte Announces Additional FDA Approval of Opzelura®? (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Incyte Announces Executive Changes, Effective August 25, 2025

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Actuate Therapeutics, Inc. to Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Price target increased by 7.2% to US$80.83

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Incyte Corporation Announces Departure of Christiana Stamoulis as Executive Vice President, Effective September 16, 2025

Consensus EPS estimates increase by 18%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Raises Revenue Guidance for the Fiscal Year 2025

Executive VP & Chief Medical Officer recently sold US$1.0m worth of stock

Incyte Corporation to Report Q2, 2025 Results on Jul 29, 2025

Insider recently sold US$743k worth of stock

Incyte Corporation Announces Chief Executive Officer Changes

Incyte Announces Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis

Incyte Announces FDA Approval of Monjuvi®? in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Incyte Announces Phase 3 Data for it's Retifanlimab (Zynyz®?) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Incyte Corporation Announces FDA Approval of Zynyz (Retifanlimab-Llwr) Making It the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Incyte Corporation, Annual General Meeting, Jun 10, 2025

Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Revenue Guidance for the Year 2025

Incyte Corporation to Report Q1, 2025 Results on Apr 29, 2025

Insider recently sold US$1.3m worth of stock

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib

Lilly's baricitinib Delivered High Rates of Hair Regrowth for Adolescents with Severe Alopecia Areata in Phase 3 BRAVE-AA-PEDS Study

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% in Patients with Prurigo Nodularis at 2025 American Academy of Dermatology Annual Meeting

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025